New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
07 September 2022 - 2:15PM
Business Wire
The study found faster, less expensive, and
more engaging trials can be achieved using tech-enabled
decentralized clinical trial models
IQVIA™ (NYSE:IQV), a leading global provider of advanced
analytics, technology solutions and clinical research services to
the life sciences industry, today announced new evidence that
decentralized clinical trials (DCT) deliver measurable benefits for
patients, sites and sponsors.
With one of the first fact-based examinations of the return on
investment of DCTs, IQVIA offers tangible data that can help
sponsors calculate the overall benefit of building clinical trials
around a decentralized model. DCT models can include a range of
elements such as IQVIA’s (DCT) Platform and support services,
research nursing & phlebotomy solutions, direct-to-patient
recruitment, risk-based monitoring, electronic clinical outcomes
assessments and e-diaries that allow patients to record data
remotely.
In this analysis decentralized trials were assessed against 14
metrics across three categories – productivity, quality, and trial
delivery, to determine how a DCT approach compared to traditional
study models. The analysis found that sponsors can achieve faster,
less expensive, and more engaging trials using DCT driven
protocols. Specifically, the findings show substantial reductions
in timelines for Final Protocol to First Patient In (FPI),
timelines for FPI to Last Patient In, Screen Failure Rate, as well
as protocol deviations. The analysis highlights that, while
different trials experienced varying levels of benefits from a DCT
approach, making decentralized models part of a clinical research
strategy from the outset can lead to significant returns.
“DCTs deliver real value for patients, sites and sponsors,” said
Ronan Brown, SVP and head of Patient Centric Solutions &
Decentralized Trials. “How you deploy your DCT model will determine
the benefits delivered, ranging from improvements in patient
recruitment and participation to higher quality data.”
Click here to read the white paper “DCTs Deliver Big ROI.” To
learn more about IQVIA’s DCT platform and services, please visit
iqvia.com/decentralized-trials.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 82,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220907005113/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
IQVIA (NYSE:IQV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024